Physician profile
John C Howard
NPI 1417334343
$8,462.28
in general payments reported to CMS, 2019-2025
35 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 86% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $489 · 2021: $245 · 2022: $533 · 2023: $1,271 · 2024: $2,679 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,696.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,892.19 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,035.88 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $932.67 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $680.98 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $661.91 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $429.30 | 2021-2025 | Aklief, Epsolay, Oracea |
| Mayne Pharma Commercial LLC | $362.29 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $284.59 | 2019-2025 | |
| Genzyme Corporation | $279.75 | 2020-2025 | |
| Incyte Corporation | $267.13 | 2023-2025 | Opzelura |
| Almirall LLC | $257.66 | 2021-2024 | Klisyri |
| Revance Therapeutics, INC. | $172.10 | 2024-2025 | Daxxify |
| Genentech USA, INC. | $153.33 | 2020-2024 | Erivedge |
| Amgen INC. | $135.25 | 2021-2025 | Otezla, Otezla |
| Allergan, INC. | $120.57 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.76 | 2019-2025 | Cabtreo |
| Lilly USA, LLC | $73.95 | 2019 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Leo Pharma INC. | $64.20 | 2022 | |
| Merck Sharp & Dohme LLC | $60.16 | 2019-2023 | Keytruda |
| Verrica Pharmaceuticals INC. | $57.99 | 2023-2025 | Ycanth |
| Janssen Biotech, INC. | $53.35 | 2021-2025 | Tremfya |
| Organogenesis INC. | $45.35 | 2020-2023 | Puraply |
| Team 1, LLC | $36.53 | 2022-2023 | |
| Smith+Nephew, INC. | $34.36 | 2019-2025 | Collagenase Santyl |
| Becton, Dickinson and Company | $33.42 | 2025 | Bd Onclarity |
| Dermira, INC. | $29.43 | 2020-2021 | |
| Dermavant Sciences, INC. | $28.43 | 2024 | Vtama |
| Lnhc, INC | $22.16 | 2025 | Zelsuvmi |
| Misonix INC | $21.79 | 2021 | |
| Vyne Pharmaceuticals INC. | $19.64 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.05 | 2023 | Spevigo |
| Pfizer INC. | $17.07 | 2021 | |
| Journey Medical Corporation | $12.21 | 2022 | |
| Organon LLC | $7.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.